Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
J Vet Intern Med. 2011 Mar-Apr;25(2):285-91. doi: 10.1111/j.1939-1676.2011.0686.x. Epub 2011 Feb 11.
The cytoreductive efficacy of the individual components of multidrug chemotherapy for canine lymphoma is difficult to evaluate after complete remission.
To compare the cytoreductive efficacy of vincristine (VCR), cyclophosphamide (CPA), and doxorubicin (DXR) in dogs that received a 6-month modified version of the University of Wisconsin-Madison chemotherapy protocol (UW-25).
Twenty-nine dogs with high-grade B-cell multicentric lymphoma.
Rearranged immunoglobulin heavy chain gene fragments from lymphoma cells were amplified by polymerase chain reaction (PCR) and sequenced to prepare clone-specific primers and probes for real-time PCR. The number of lymphoma cells in peripheral blood was measured from diagnosis to week 11 of UW-25.
The number of lymphoma cells after the 1st administration of VCR, CPA, and DXR in weeks 1-4 was decreased in 29/29 (100%), 15/29 (51.7%), and 26/27 (96.3%) dogs, respectively. The cytoreductive efficacy of CPA was less than that of VCR and DXR. VCR, CPA, and DXR administered in weeks 6-9 were effective in 5/26 (19.2%), 5/20 (25.0%), and 14/19 (73.7%) dogs, respectively, indicating the sustained cytoreductive efficacy of DXR. CPA nonresponders were heavier and exhibited a shorter 1st remission than CPA responders.
When using UW-25 for treatment of canine lymphoma, CPA was found to have less cytoreductive efficacy than VCR and DXR. Real-time PCR-based quantification of tumor cells is an objective marker of the efficacy of chemotherapeutic agents.
完全缓解后，难以评估多药化疗治疗犬淋巴瘤中各成分的细胞减灭效果。
比较长春新碱（VCR）、环磷酰胺（CPA）和多柔比星（DXR）在接受威斯康星大学麦迪逊分校 6 个月改良化疗方案（UW-25）的犬中的细胞减灭效果。
29 只患有高级 B 细胞多中心淋巴瘤的犬。
通过聚合酶链反应（PCR）扩增淋巴瘤细胞中的重链免疫球蛋白基因片段，并测序以制备用于实时 PCR 的克隆特异性引物和探针。从诊断到 UW-25 的第 11 周，测量外周血中的淋巴瘤细胞数。
在第 1 周至第 4 周的 VCR、CPA 和 DXR 首次给药后，29/29（100%）、15/29（51.7%）和 26/27（96.3%）犬的淋巴瘤细胞数量减少。CPA 的细胞减灭效果不如 VCR 和 DXR。在第 6 周到第 9 周给予的 VCR、CPA 和 DXR 分别在 5/26（19.2%）、5/20（25.0%）和 14/19（73.7%）犬中有效，表明 DXR 具有持续的细胞减灭效果。CPA 无反应者的体重较重，且第 1 次缓解期较短。
在使用 UW-25 治疗犬淋巴瘤时，发现 CPA 的细胞减灭效果不如 VCR 和 DXR。基于实时 PCR 的肿瘤细胞定量是化疗药物疗效的客观标志物。
